Almere

• Neoadjuvant immune checkpoint inhibition and novel IO combinations in early-stage colon cancer - the NICHE trial Recruiting
  2024-513314-35-00 4 2017-01-20 Adenocarcinoma of the Colon or rectosigmoid (considered as non-rectal)
• Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a) ( MOVE-Lp(a) ) Ended recruitment
  2025-521067-13-00 5 2026-04-24 Atherosclerotic Cardiovascular Disease (ASCVD)
• First line treatment with VeNEtoclaX and ibruTinib induction followed by obinutuzumab intenSificaTion Exclusively in CLL/SLL Patients not in … Ended recruitment
  2022-502808-72-00 4 2024-09-11 Chronic Lymphocytic Leukemia
• MAD Ended recruitment
  2024-516379-34-00 6 2024-08-02 Myopia
• Personalized extended interval dosing of natalizumab in relapsing remitting multiple sclerosis (NEXT-MS) Ended recruitment
  2024-513105-31-00 6 2024-07-30 Multiple Sclerosis
• The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-OUTCOMES) Ended recruitment
  2023-508630-34-00 5 2024-05-28 Overweight
• A Phase 3 Randomized Study Comparing Talquetamab in Combination with Pomalidomide (Tal-P), Talquetamab in Combination with Teclistamab (Tal- … Ended recruitment
  2022-502446-27-00 5 2024-02-26 Relapsed or Refractory Myeloma
• Aspirin to prevent cardiovascular events in patients with pneumonia or influenza Ended recruitment
  2023-504553-12-01 6 2023-12-27 Influenza
• A Phase 3/3b, Randomized, Observer-blind, Multicenter Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of Fluad and Fluad … Ended recruitment
  2022-503004-24-00 5 2023-10-20 Influenza virus
• DUPI REDUCE trial (DUPIlumab dose REDUCtion in patients with controlled atopic Eczema): a multicenter, low-intervention, non-inferiority ran … Ended recruitment
  2023-504171-24-00 6 2023-08-14 Atopic eczema
• Noisy Rebels; Non-inferiority study of rituximab compared to ocrelizumab in relapsing MS Ended recruitment
  2022-502664-21-00 6 2023-05-01 multiple sclerosis
• Does progesterone luteal phase support increase live birth rates in couples undergoing intra-uterine insemination with Mild Ovarian HyperSti … Ended recruitment
  2022-501534-33-00 6 2023-03-06 Unexplained Subfertility, infertility
• Personalized dosing of ocrelizumab in MS Ended recruitment
  2024-513193-22-00 11 2022-03-16 Multiple Sclerosis
• Safe shortening of antibiotic treatment duration for complicated Staphylococcus aureus bacteremia (SAFE-trial) Ended recruitment
  2024-515398-90-01 5 2020-08-17 Staphylococcus aureus bacteremia
• Liposomal iRInotecan, Carboplatin or oXaliplatin in the first line treatment of esophagogastric cancer: a randomized phase 2 study (LyRICX) Ended recruitment
  2023-509287-26-00 4 2019-07-01 previously untreated metastatic or locally advanced esophagogastric ca
• This study is being done to test the effectiveness and safety of an investigational drug called acalabrutinib (ACP-196) when taken with alre … Ended recruitment
  2023-509349-11-00 5 2019-03-22 Previously untreated Chronic Lymphocytic Leukemia Without del(17p) or
• HOVON 152 DLBCL. A phase II study evaluating the effect of DA-EPOCH-R induction followed by nivolumab consolidation in patients with newly d … Ended recruitment
  2022-501038-48-00 4 2018-07-26 Diffuse Large B-Cell Lymphoma
• A Randomized, Open-label, Phase 3 study of the Combination of Ibrutinib plus Venetoclax versus Chlorambucil plus Obinutuzumab for the First- … Ended recruitment
  2023-503469-49-00 5 2018-04-19 Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)
• Endocrine therapy plus CDK 4/6 inhibition in first- or second-line for hormone receptor positive advanced breast cancer - the SONIA study Ended recruitment
  2024-516204-42-00 5 2017-11-21 Breast cancer
• Treatment of peritoneal dissemination in stomach cancer patients with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy; P … Ended recruitment
  2023-510159-53-01 4 2017-09-28 peritoneal dissemination in stomach cancer patients
• Randomized, Embedded, Multifactorial Adaptive Platform trial for Community-Acquired Pneumonia (REMAP-CAP) Ended recruitment
  2023-507889-89-00 5 2016-02-19 Respiratory tract infection
• WOMEN&More: Efficacy, safety, and acceptability of mifepristone 50 mg once-weekly as a contraceptive Ended
  2022-502694-41-00 5 2025-04-14 Contraception
• The efficacy and the safety of two doses of CHF6001 for the treatment of Chronic Obstructive Pulmonary Disease (COPD) Ended
  2023-510175-60-00 5 2021-06-16 Chronic obstructive pulmonary disease (COPD) and Chronic Bronchitis
• A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes (SURPASS-CV … Ended
  2023-507846-96-00 5 2020-06-19 Type 2 Diabetes Mellitus

Showing 25–48 of 51 trials